All rights reserved. No reuse allowed without permission.

- 12. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
- 13. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
- 14. Section for Pharmacology and Pharmaceutical Department of Pharmacy,
- University of Oslo, Oslo, Norway
-
- ¶: both authors contributed equally to this work.
-
- ***Corresponding author**
- E-mail: martahh1@blanquerna.url.edu (MHH)

ABSTRACT (286 words)

 Background: Intrauterine exposure to antiseizure and antidepressant drugs is associated with adverse pregnancy outcomes, including low birth weight. Gene variants in placental efflux transporter genes may alter foetal exposure to these drugs.

 Methods: We investigated whether genetic variants in placental efflux transporters modified the impact of maternal antiseizure and antidepressant drug use on offspring birth weight, using data from the Norwegian Mother, Father and Child Cohort Study and the Medical Birth Registry of Norway (69,828 offspring with their genotype data, 81,189 with maternal genotype data). We systematically searched for gene variants in placental efflux transporters influencing drug exposure [MDR1-*ABCB1* (7 alleles), MRP1-*ABCC1* (2), MRP2-ABCC2 (3) and, BCRP-*ABCG2* (2)] and calculated genetic scores (sum of alleles potentially related to low transporter activity). We assessed the interaction between prenatal drug use and genetic scores on birth weight.

 Findings: Prenatal antiseizure medication exposure was associated with lower birth weight (-95.5 grams, 95% CI -190 to -0.78). This relationship depended on the offspring's MRP2-*ABCC2* genetic score. Birth weight differences between exposed vs. unexposed were 70.3 g (95% CI -494 to 634) in the lowest genetic score category and -306 g (95% 55 CI -361 to -31.8) in the highest (interaction p -value = 0.019; main variant: rs3740066). The antiseizure medication-lower birth weight association also depended on the maternal MDR1-*ABCB1* genetic score. Birth weight differences between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category and -317 g (95% CI -517 to -117) in the highest (interaction p -value = 0.037; main variants: rs10248420 and rs2235015). Prenatal antidepressant exposure was associated with low birth weight, but no gene-drug interactions were observed.

 Conclusions: MRP2-*ABCC2* and MDR1-*ABCB1* variants may influence prenatal antiseizure medication's impact on neonatal birth weight.

 Keywords: antiseizure medication, birth weight, MRP2-*ABCC2*, MDR1-*ABCB1*, MoBa, MBRN.

SUMMARY

What is already known on this topic.

- Low birth weight increases the risk of neonatal death, morbidity, and lifelong susceptibility to various health conditions, including neurodevelopmental, cardiometabolic, respiratory, and psychiatric disorders.
- Previous studies have reported an association between maternal use of centrally acting medication during pregnancy and low birth weight in the offspring, but the underlying causes remain poorly understood.
- It is of great concern to identify strategies that can modulate foetal exposure to these medications and enable individualised, safe use since discontinuation may also increase the risk of harm to the mother.

What this study adds.

- 80 Our study uncovered genetic variants in both offspring (rs3740066) and mother (rs10248420 and rs2235015) linked to placental efflux transporters that modulated the association between maternal antiseizure drug use during pregnancy and the risk of low birth weight in the offspring, marking the first exploration of such interactions.
- If these findings are confirmed and information about specific drugs is incorporated, this could potentially be used in the development of personalized recommendations for pregnant women undergoing these treatments.

88 **INTRODUCTION**

89

 The use of medication during pregnancy must carefully balance benefits to the mother 91 and potential harm to the offspring.¹ Centrally acting drugs (such as antiseizure drugs [mainly lamotrigine, 0.3% of pregnancies] and antidepressants [1.5% of pregnancies]) 93 have been increasingly used during pregnancy.^{$2,3$} However, intrauterine exposure to these medications may be associated with adverse pregnancy outcomes such as 95 impaired foetal growth and reduced birth weight in offspring.⁴⁻⁶ Furthermore, these conditions are linked to a multitude of morbidities, resulting in both immediate and long-97 term adverse consequences for newborns, their families, and society.⁷ The placenta plays an essential role in substance exchange between mother and foetus (e.g., nutrients, metabolic by-products). Small, non-polar, lipophilic xenobiotics such as antiseizure drugs and antidepressants can pass through the placenta via passive 101 diffusion.⁸ However, several active proteins can efflux these compounds from the foetus 102 back to the mother.⁹ Active efflux proteins from the adenosine triphosphate-binding cassette superfamily (such as P-glycoprotein, breast cancer resistance protein, and others multidrug resistance proteins) are involved in the transplacental passage of drugs 105 particularly affecting the passage of centrally-acting drugs and their metabolites.^{10,11} 106 Several antiseizure drugs and antidepressants are substrates for these transporters.^{12,13} Efflux transporters may therefore have a foetoprotective effect by lowering the concentrations of potentially toxic drugs on the foetal side. Genetic variants in the transporters may modify their activity and could be located in the offspring or maternal 110 genotype. ^{14,15} Little is known about the role of genetic variants in placental efflux transporters on the modulation of the association of antiseizure drugs and antidepressants during pregnancy with offspring outcomes such as low birth weight.

113 Our aim was to explore whether there is an interaction between the use of 114 antiseizure drugs or antidepressants during pregnancy and genetic variants related to

- All rights reserved. No reuse allowed without permission.
- 115 placental efflux transporters (in P-glycoprotein, breast cancer resistance protein, and
- 116 others multidrug resistance proteins) on offspring birth weight.

MATERIALS AND METHODS

Study participants

 We included participants in the Norwegian Mother, Father, and Child Cohort Study (MoBa). MoBa is a prospective, population-based pregnancy cohort conducted by the Norwegian Institute of Public Health. Pregnant women and their partners were recruited 123 across Norway between 1999-2008 at the time of routine ultrasound screening $(-17th)$ gestational week). The cohort includes approximately 114,000 children, 95,000 mothers, and 75,000 fathers.

 This work used a subsample of offspring from singleton pregnancies with available information on genotype and birth weight (from version #12 of the quality- assured data files released on May 11, 2022). Genotype data was obtained from blood samples provided during pregnancy and at birth (mothers) and umbilical cord blood at 130 birth (offspring).¹⁶ A total of 238,001 samples have been genotyped in 24 genotyping 131 batches with varying selection criteria, genotyping platforms, and genotyping centres.¹⁷ Quality control, phasing, and imputation were performed using the MoBaPsychGen 133 pipeline as previously described.¹⁷

 Our work is described according to the Strengthening the Reporting of 135 Observational studies in Epidemiology guidelines (Supplemental Table 3).¹⁸

Use of centrally acting drugs

 We used self-reported information on the use of centrally acting drugs from MoBa 139 questionnaires in the 18th and 30th gestational weeks.¹⁹ Specifically, women were asked whether they had epilepsy or depression, and if they answered yes, whether any medications were used to treat the condition(s). This project has no information on the specific drug(s) the woman used. Any reported use of medication(s) for epilepsy (yes/no) or depression (yes/no) were categorized and evaluated separately.

Birth weight

Data on offspring birth weight in grams was obtained from the Medical Birth Registry of

- Norway, a national health registry which contains information about all births in Norway
- 148 since 1967.²⁰
-
- *Covariates*

151 Information on maternal age at delivery (continuous), parity (1, 2, 3, \geq 4) and sex of the offspring (female/male) was obtained from the birth registry. Furthermore, information on maternal years of education (continuous), pre-pregnancy body mass index (continuous), having ever smoked (yes/no), and self-reported depression or epilepsy was gathered in the questionnaire administered at gestational week 18.

Genetic variants related to placental transporters and genetic scores.

 We performed a systematic review in PubMed, Web of Science, pharmacogenetic websites [\(https://www.pharmgkb.org\)](https://www.pharmgkb.org/) and GWAS catalog (https://www.ebi.ac.uk/gwas/) to identify gene variants on the adenosine triphosphate-binding cassette superfamily of placental efflux transporters (MDR1-*ABCB1*, MRP1-*ABCC1,* MRP2-*ABCC2*, and BCRP- *ABCG2*). We followed the recommendations of the Preferred Reporting Items for 163 Systematic reviews and Meta-Analyses statement.²¹ A detailed description of the search is available in Supplemental Materials.

 After the systematic review, we only conserved genetic variants that were not in linkage disequilibrium according to linkage disequilibrium block analysis in the 1000 Genomes CEU and GBR populations (given the MoBa participants passing the post-168 imputation quality control cluster with these populations; R^2 < 0.8) and with a minor allele 169 frequency $> 1\%$ ²² Genetic scores were calculated as the sum of the number of risk alleles for all genetic variants related to each transporter in a participant. The genetic score was represented in the results as a genetic score if the number of score values were ≤5. Otherwise, we represented them in quartiles. We considered a risk allele to be

 the allele associated with any of these five theoretical situations potentially related to an increased exposure of the drug to the foetus: decreased function of the transporter, declined expression of the transporter, non-resistance to the treatment, higher concentrations of the drug, or more adverse effects. Information related to the studies is available in Supplemental Table 2.

Ethical approval

 The MoBa study is conducted according to the Declaration of Helsinki for medical research involving human subjects. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency. It is now based on regulations related to the Norwegian Health Registry Act. Participants provided written informed consent before joining the cohort. This project was approved by the Regional Committee for Medical and Health Research Ethics of South/East Norway (reference: 2017/1362).

Statistical analyses

 Normally distributed continuous variables were described by means and standard 190 deviations, nonnormally distributed continuous variables by medians and $25th$ -75th percentiles, and categorical variables by proportions.

 We first assessed the relationship between maternal use of centrally acting drugs during pregnancy and birth weight using multivariable linear regressions adjusted for offspring sex and maternal factors (age at delivery, years of education, pre-pregnancy body mass index, parity and having ever smoked). Clustered standard errors were computed to account for dependence among births to mothers contributing with more than one pregnancy in MoBa. To determine whether there were significant interactions between maternal prenatal use of centrally acting drugs and the genetic scores on the offspring birth weight, we applied likelihood ratio tests between nested linear regression models with and without an interaction product-term of "exposure group × genetic score".

 The nested models were further adjusted for the first twenty ancestry-informative genetic principal components and genotyping batch. We considered any interaction with a *p*- value for the overall interaction test < 0.05 and a differential association between medication use and offspring birth weight in the two extreme categories according to the genetic score. Whether an interaction was found, we further explored interactions with the individual variants in the genetic score as sensitivity analyses using the same strategy (as these were exploratory sensitivity analyses, we here considered any interaction with a *p*-value < 0.1).

Statistical analyses were performed in R Software, version 4.1.0. Our analysis

- code is available in GitHub:
- [https://github.com/alvarohernaez/Gene_psychoactivedrug_BW_MoBa/.](https://github.com/alvarohernaez/Gene_psychoactivedrug_BW_MoBa/)

RESULTS

-
- *Study population*
- In our study, we included 69,828 singleton pregnancies with offspring genotype
- information and offspring birth weight, and 81,189 singleton pregnancies with maternal
- 217 genotype data and offspring birth weight (Figure 1). Mean birth weight was 3,639 grams
- (SD 522). A total of 174 children (0.25%) were exposed to maternal use of antiseizure
- drugs during pregnancy and 766 (1.10%) to antidepressants. Women using centrally
- acting drugs were younger (only for antiseizure drugs), had lower educational attainment,
- and were more likely to have ever smoked (Table 1).
-
-
- **Figure 1.** Flow chart of study participants.
-

227 **Table 1.** Baseline characteristics of mothers with offspring genotype information.

Search of genetic variants on placental transporters

 The systematic search identified 26 genetic variants in the placental transporter genes associated with differences in antiseizure drugs and/or antidepressant outcomes (Supplemental Figure 1), of which 14 were independent and available in the MoBa genotype database (Supplemental Table 1). Seven variants were found for MDR1- *ABCB1*, two for MRP1-*ABCC1,* three for MRP2-*ABCC2*, and two for BCRP-*ABCG2*. We used these genetic variants to calculate risk scores. The ranges of values for the four genetic scores calculated were: 0 to 11 (MDR1-*ABCB1*; we presented the stratified associations according to quartiles), 0 to 4 (MRP1-*ABCC1*), 2 to 6 (MRP2-*ABCC2*), and 0 to 4 (BCRP-*ABCG2*).

 Interaction between genetic variants of placental transporters and exposure to antiseizure drugs during pregnancy on birth weight

 Antiseizure medication use during pregnancy was associated with lower birth weight (- 95.5 g, 95% confidence interval [CI] -190 to -0.78). Greater values of the MRP2-*ABCC2* genetic score in the offspring were associated with lower birth weight in offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed was 70.3 g (95% CI -494 to 634) in the lowest genetic score category (2 risk alleles) and -306 g (95% CI -361 to -31.8) in the highest (6 risk 249 alleles) (*p*-value for interaction = 0.019; Figure 2). The variant with the strongest evidence of an interaction in the sensitivity analyses of the MRP2-*ABCC2* genetic score was 251 rs3740066 (p -value for interaction = 0.023; Supplemental Figure 2).

 Greater values of the MDRP1-*ABCB1* genetic score in the mother were also linked to lower birth weight among offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category (first quartile) and - 256 317 g (95% CI -517 to -117) in the highest (fourth quartile) (*p*-value for interaction $=$ 0.037; Figure 3). Variants rs10248420 and rs2235015 included in the MDRP1-*ABCB1*

All rights reserved. No reuse allowed without permission.

- 258 genetic score had some evidence of an interaction in the sensitivity analyses (*p*-values
- 259 for interactions = 0.042 and 0.058, respectively; Supplemental Figure 3).

Figure 2. Differences in birth weight associated with pregnancy exposure to antiseizure medication due to the genetic scores for placental

 Figure 3. Differences in birth weight associated with pregnancy exposure of antiseizure medication due to the genetic scores for placental transporters in the mother.

- 266 *Interaction between genetic variants of placental transporters and exposure to antidepressants*
- 267 *during pregnancy on birth weight*
- 268 Use of antidepressant drugs during pregnancy was associated with lower birth weight (-60.5
- 269 g, 95% CI -97.6 to -23.3). However, we observed no interactions between prenatal use of
- 270 antidepressants and any genetic score of placental efflux transporters (in offspring or mothers)
- 271 on birth weight in the offspring (Supplemental Figures 4 and 5).

DISCUSSION

 In this large population-based study, involving offspring of mothers who used antiseizure medication during pregnancy, a high genetic score for MRP2-*ABCC2* in the offspring and MDR1-*ABCB1* in the mother, suggesting a greater exposure to these drugs, was associated with lower birth weight in the offspring.

 MDR1-*ABCB1* and MRP2-*ABCC2* are the only transporters located in the apical membrane of the trophoblast (maternal side) and their function is to return xenobiotics to 280 maternal circulation.²³ Thus, it seems plausible that genetic variants linked to lower transporter activity are associated with higher foetal exposure and greater toxicity of antiseizure drugs. In addition, the main variant in the interaction between the MRP2-*ABCC2* genetic score and prenatal antiseizure drug use (rs3740066) has been previously linked to a poorer response to 284 antiseizure medication²⁴ and a higher risk of other adverse events during pregnancy 285 (intrahepatic cholestasis of pregnancy).²⁵ The differences in the interactions found within genetic variants in the offspring (MRP2-*ABCC2*) and maternal genome (MDR1-*ABCB1*) can be explained by physiological changes in the placenta structure. Early in pregnancy, the separation between the maternal circulation and the foetal circulation by the trophoblasts villous barrier is 50-100 μm (second month). It becomes progressively thinner as the 290 pregnancy proceeds (only 4-5 μ m at term).²⁶ In addition, the total placenta surface area 291 increases from about 5 m² at 28 weeks of gestation to 12 m² at term. Thus, passive diffusion of medications increases with gestational age, which means that medication can reach the 293 foetal circulation more easily later in pregnancy.²⁶ At the same time, the expression of MRP2- *ABCC2* increases with advancing gestational age, whereas the expression of MDR1-*ABCB1* 295 declines.^{27,28} As a consequence of all these phenomena, the presence of risk alleles for MRP2- *ABCC2* may play a more significant role in determining the offspring's exposure. However, an alternative hypothesis could also explain our findings. A greater foetal exposure to medication due to lower activity of the efflux transporters may also be linked to lower medication levels in the mother and a poorer control of the disease. Greater disease effects in mothers may be

 associated with alternative mechanisms that may also explain an increased risk of low birth weight in the offspring.

 There could be several reasons for the lack of gene-drug interactions with antidepressants. First, the association between exposure to antidepressants during pregnancy and birth weight is of a smaller magnitude in our data, which can make the search of gene- drug interactions more challenging. Second, the accuracy of our data regarding the usage of antidepressants may be less precise, as women may have varying criteria for identifying such treatments. This discrepancy may not be present regarding antiseizure drugs. Finally, a larger proportion of women may discontinue the use of antidepressants during pregnancy compared 309 to antiseizure medications.²⁹

 Our study has some limitations. First, due to the unavailability of information on the specific drug utilized, we conducted our analysis based on aggregated drug groups. Although the main medications in each group show similar pharmacodynamic behaviour and their usage 313 during pregnancy reduces the number of medications under consideration, this may interfere with our findings because there may be variations in the medication groups' interactions due 315 to differences in transporter affinity or dose-dependent effects.^{26,30} Second, due to the lack of a genome-wide association study showing which genetic variants are associated with high or low activity of efflux transporters, we calculated risk scores using studies on genetic variants indirectly related to high or low activity (e.g., treatment resistance, treatment efficacy, presence of adverse effects). Third, the interactions found in our data are only suggestive and our findings require replication in independent populations to confirm their validity. Finally, the characteristics of our participants (individuals of northern European ancestry with moderate- high socioeconomic status) limit our capacity to generalize our conclusions to other populations.

CONCLUSIONS

 In summary, genetic variants in MRP2-*ABCC2* and MDR1-*ABCB1* placental transporters may modulate the association between prenatal exposure to antiseizure drugs and low birth weight in the offspring. To the best of our knowledge, this is the largest gene-drug interaction study on offspring birth weight to date and it was performed in a well-characterized population with genome-wide genotype information. If our findings are confirmed, particularly in studies in which we know exactly which drug the mothers have used during pregnancy, the assessment of these genetic variants may be implemented in clinical settings to support safer use of antiseizure drugs during pregnancy.

DATA AVAILABILITY STATEMENT

 Consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to datasets for replication should apply to [datatilgang@fhi.no.](mailto:datatilgang@fhi.no) Access to datasets requires approval from the Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.

ACKNOWLEDGMENTS

 The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We thank all the participating families in Norway who take part in this ongoing cohort study, and those who contributed to the recruitment and the infrastructure of the cohort.

 We thank the Norwegian Institute of Public Health for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (project reference: #229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (project reference: #223273), South East Norway Health Authority, and Stiftelsen Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research (University of Bergen) for providing genotype data funded by the European Research Council Advanced Grant project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authority.

 This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated, and developed by the TSD service group at the University of Oslo, IT-Department (tsd-drift@usit.uio.no).

 This paper does not necessarily reflect the position or policy of the Norwegian Research Council.

-
-

FUNDING

 The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Norwegian Ministry of Education and Research. This project received funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement No 947684). This work was also partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 262700 and 223273, and the project "Women's fertility – an essential component of health and well-being", number 320656, and co-funded by the European Research Council (grant agreement No 101071773). M.H.H. was supported by the fellowship "*Estancias de movilidad Jose Castillejo dentro del Programa Estatal de Promoción del Talento y su empleabilidad, en el marco del Plan Estatal de lnvestigación Científica y Técnica y de lnnovación 2017-2020",* from the Spanish government. P.R.N. was supported by the European Research Council (grant agreement No 293574), the Novo Nordic Foundation (#NNF19OC0054741) and the Trond Mohn Foundation (PRECISE-DIA). E.C. and A.Havdahl were supported by the Research Council of Norway (274611) and the South-Eastern Norway Regional Health Authority (project numbers 2020022, 2021045). O.A.A. was supported by the European Research Council (grant agreement No 964874) and the Research Council of Norway (300309, 273291). The funders had no role in the study design; the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Views and opinions expressed in this paper are those of the authors only and do not necessarily reflect those of the funders. Neither the European Union nor the granting authority can be held responsible for them.

CONFLICTS OF INTEREST

 O.A.A. is a consultant for cortechs.ai and has received speaker's honorarium from Janssen, Lundbeck, and Sunovion unrelated to the current work. The rest of the authors declare that no competing interests exist.

AUTHORS' CONTRIBUTION

 M.H.H. conceived and designed the study, was responsible for data curation, formal analyses, data interpretation, and drafting the article. J.M.C. critically revised the article and contributed to interpretation of the data. K.H.S. provided support in data analysis, software use, and visualization of results, and critically revised the article. T.K.W.G. was involved in the interpretation of data and critically revised the article. Y.L. contributed to data acquisition and critically revised the article. P.M. contributed to data acquisition and critically revised the article. P.R.N. contributed to data acquisition and critically revised the article. O.A.A. contributed to data acquisition and critically revised the article. E.C. contributed to data acquisition and critically revised the article. A.Havdahl contributed to data acquisition and critically revised the article. E. Molden critically revised the article. S.E.H. contributed to data acquisition, obtained funding, and critically revised the article. K.F. provided support in data analysis and critically revised the article. M.C.M. and A.Hernaez coordinated the project, contributed to data interpretation, and critically revised the article. M.H.H. and A.Hernaez are the guarantors of this study, accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

REFERENCES

 1. Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017;16: 1181–1190. doi:10.1080/14740338.2017.1363177

2. Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS,

et al. The international prevalence of antidepressant use before, during, and after pregnancy:

 A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord. 2020;264: 82–89. doi:10.1016/j.jad.2019.12.014

 3. Cohen JM, Cesta CE, Furu K, Einarsdóttir K, Gissler M, Havard A, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006‐2016: A study in the five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020;29: 913–922. doi:10.1002/pds.5035

 4. Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, et al. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. PLoS One. 2019;14: e0214180. doi:10.1371/journal.pone.0214180

 5. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261: 579–588. doi:10.1007/s00415-013-7239-x

 6. Wartko PD, Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA, et al. Association of antidepressant continuation in pregnancy and infant birth weight. J Clin Psychopharmacol. 2021;Publish Ahead of Print: 403. doi:10.1097/jcp.0000000000001410

 7. Ashorn P, Ashorn U, Muthiani Y, Aboubaker S, Askari S, Bahl R, et al. Small vulnerable newborns—big potential for impact. Lancet. 2023;401: 1692–1706. doi:10.1016/s0140- 6736(23)00354-9

 8. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol. 2006;2: 51–69. doi:10.1517/17425255.2.1.51

 9. Wang J-S, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev. 2007;39: 723–746. doi:10.1080/03602530701690390

 10. Joshi AA, Vaidya SS, St-Pierre MV, Mikheev AM, Desino KE, Nyandege AN, et al. Placental ABC transporters: Biological impact and pharmaceutical significance. Pharm Res.

2016;33: 2847–2878. doi:10.1007/s11095-016-2028-8

 11. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43: 487–514. doi:10.2165/00003088-200443080-00001

 12. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: Update of the literature. Clin Pharmacokinet. 2015;54: 709–735. doi:10.1007/s40262-015-0267-1

 13. Goetzl L, Darbinian N, Merabova N, Devane LC, Ramamoorthy S. Gestational age variation in human placental drug transporters. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.837694

 14. Daud ANA, Bergman JEH, Bakker MK, Wang H, de Walle HEK, Plösch T, et al. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014;15: 1029–1041. doi:10.2217/pgs.14.62

 15. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D. Placental transfer of antidepressant medications: Implications for postnatal adaptation syndrome. Clin Pharmacokinet. 2015;54: 359–370. doi:10.1007/s40262-014-0233-3

 16. Paltiel L, Haugan A, Skjerden T, et al. The biobank of the Norwegian Mother and Child Cohort Study–present status. Norsk Epidemiologi. 2014;24: 29–35. Available: https://www.ntnu.no/ojs/index.php/norepid/article/view/1755/1752

 17. Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. bioRxiv. 2022. p. 2022.06.23.496289. doi:10.1101/2022.06.23.496289

 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61: 344–349. doi:10.1016/j.jclinepi.2007.11.008

 19. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort profile update: The Norwegian mother and child cohort study (MoBa). Int J Epidemiol. 2016;45: 382– 388. doi:10.1093/ije/dyw029

 20. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years: Thirty years' birth registration. Acta Obstet Gynecol Scand. 2000;79: 435–439. doi:10.1034/j.1600-0412.2000.079006435.x

 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. doi:10.1136/bmj.n71

 22. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population- specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31: 3555–3557. doi:10.1093/bioinformatics/btv402

 23. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 11 1999;104: 1441–1447. doi:10.1172/jci7963

 24. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2 polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647–651. doi:10.1111/j.1755-5949.2012.00336.x

 25. Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol. 2008;48: 125–132. doi:10.1016/j.jhep.2007.08.015

26. Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E. Placental control of drug delivery.

Adv Drug Deliv Rev. 2017;116: 63–72. doi:10.1016/j.addr.2016.08.002

 27. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of mrp2 (abcc2) in human placenta: Influence of gestational age and cellular differentiation. Drug Metab Dispos. 2005;33: 896–904. doi:10.1124/dmd.104.003335

 28. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27: 602–609. doi:10.1016/j.placenta.2005.05.007

29. Cohen JM, Selmer R, Furu K, Karlstad Ø. Interrupted time series analysis to assess

changes in prescription filling around conception and implications for exposure

misclassification. Pharmacoepidemiol Drug Saf. 2020;29: 745–749. doi:10.1002/pds.4974

30. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and

SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target.

2012;20: 736–763. doi:10.3109/1061186x.2012.716847

SUPPORTING INFORMATION

TABLE OF CONTENTS

SUPPLEMENTAL MATERIALS

Search strategy of genetic variants

 All studies that examined the association between the placental transporters of interest and epilepsy or depression were researched. We systematically searched PubMed, Web of Science, pharmacogenetic websites [\(https://www.pharmgkb.org\)](https://www.pharmgkb.org/) and GWAS catalog [\(https://www.ebi.ac.uk/gwas/home\)](https://www.ebi.ac.uk/gwas/home). All databases were searched using the Boolean method with the following terms (1 AND 2 AND 3): 1) "antiseizure" OR "antiepilepsy" OR "anticonvulsants" OR "antidepressant" OR "benzodiazepines"; 2) "polymorphism" OR "genetic polymorphism" OR "genetic variant" OR "pharmacogenetics"; 3) "ATP binding cassette" or "ABCB1" OR "ABCC1" OR "ABCC2" OR "ABCG2" OR "ABCC5" OR "ABCC3". In addition, the reference and discussions of all pooled articles were carefully scanned for additional publications. We excluded studies: 1) not performed in humans; 2) not published in English; 3) not published in scientific journals; and 4) focused on other drug groups.

All rights reserved. No reuse allowed without permission.

540 **SUPPLEMENTAL TABLES**

541

542 **Supplemental Table 1.** Expected risk allele for birth weight in efflux transporters.

545 **Supplemental Table 2.** The articles detail the development of the expected risk allele for the transporter score.

All rights reserved. No reuse allowed without permission.

548 **Supplemental Table 3.** STROBE checklist for cohort studies 549

551 **SUPPLEMENTAL RESULTS**

552

553 **Supplemental Figure 1**. Flow chart of the systematic literature review of genetic variants on

- 554 placental efflux transporters.
- 555

556 **Supplemental Figure 2.** Differences in birth weight associated with pregnancy use of

557 antiseizure drugs due to *ABCC2* individual genetic variants in the offspring.

All rights reserved. No reuse allowed without permission.

559 **Supplemental Figure 3**. Differences in birth weight associated with pregnancy use of

560 antiseizure drugs due to *ABCB1* individual genetic variants in the mother.

561

Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy
(95% confidence interval) (95% confidence interval)

Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy
(95% confidence interval)

562 **Supplemental Figure 4.** Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in
563 the offspring. the offspring.

 Supplemental Figure 5. Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the mother.

 SUPPLEMENTAL REFERENCES

 1. Hung C-C, Jen Tai J, Kao P-J, Lin M-S, Liou H-H. Association of polymorphisms inNR1I2andABCB1genes with epilepsy treatment responses. Pharmacogenomics. 2007;8: 1151–1158. doi:10.2217/14622416.8.9.1151

 2. Kwan P, Baum L, Wong V, Ng PW, Lui CHT, Sin NC, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav. 2007;11: 112–117. doi:10.1016/j.yebeh.2007.04.013

 3. Shaheen U, Prasad DKV, Sharma V, Suryaprabha T, Ahuja YR, Jyothy A, et al. Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res. 2014;108: 251–256. doi:10.1016/j.eplepsyres.2013.11.009

 4. Zhang M-L, Chen X-L, Bai Z-F, Zhao X, Li W-X, Wang X-Y, et al. ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients. Gene. 2021;805: 145907. doi:10.1016/j.gene.2021.145907

 5. Fan Y-X, Zhang Z, Meng J-R, Yin S-J, Wang P, Zhou T, et al. Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis. Epilepsy Res. 2021;177: 106785. doi:10.1016/j.eplepsyres.2021.106785

 6. Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. J Psychopharmacol. 2019;33: 522–531. doi:10.1177/0269881119827959

 7. Li M, Tan J, Yang X, Su L, Xie J, Liang B, et al. The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy Res. 2014;108: 1052–1067. doi:10.1016/j.eplepsyres.2014.03.019

 8. Shen X-M, Cheng J. Effects ofMDR1(C3435T) polymorphism on resistance, uptake, and efflux to antiepileptic drugs. DNA Cell Biol. 2019;38: 250–255. doi:10.1089/dna.2018.4553

 9. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics. 2014;15: 1867–1879. doi:10.2217/pgs.14.142

 10. Huang X, Yu T, Li X, Cao Y, Li X, Liu B, et al. ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients. Pharmacogenomics. 2013;14: 1723–1730. doi:10.2217/pgs.13.151

 11. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57: 203–209. doi:10.1016/j.neuron.2007.11.017

 12. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013;14: 35–45. doi:10.2217/pgs.12.180

 13. Lee S-T, Ryu S, Kim S-R, Kim M-J, Kim S, Kim J-W, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol. 2012;32: 441–448. doi:10.1097/jcp.0b013e31825ac35c

 14. Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D. ABCB1gene variants and antidepressant treatment outcome: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168: 274–283. doi:10.1002/ajmg.b.32309

 15. de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013;13: 349–353. doi:10.1038/tpj.2012.16

16. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM.

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.

Pharmacogenet Genomics. 2010;20: 467–475. doi:10.1097/fpc.0b013e32833b593a

 17. Breitenstein B, Scheuer S, Brückl TM, Meyer J, Ising M, Uhr M, et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res. 2016;73: 86–95. doi:10.1016/j.jpsychires.2015.11.010

 18. Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana MT, et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014;14: 457–462. doi:10.1038/tpj.2014.12

631 19. Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, et al. Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy: CAE Pharmacogenetics. Ann Neurol. 2017;81: 444–453. doi:10.1002/ana.24886

 20. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008;32: 398–404. doi:10.1016/j.pnpbp.2007.09.003

 21. Mittal B, Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK. Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum Genet. 2011;17: 32. doi:10.4103/0971-6866.80357

642 22. Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. Ther Drug Monit. 2012;34: 518–525. doi:10.1097/ftd.0b013e31826517c6

 23. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics J. 2018;18: 422–430. doi:10.1038/tpj.2017.38

 24. Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, et al. Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics. 2012;13: 1119–1127. doi:10.2217/pgs.12.86

 25. Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Cheong KC, Ismail Z, et al. G2677T polymorphism can predict treatment outcome of Malaysians with complex partial seizures being treated with Carbamazepine. Genet Mol Res. 2013;12: 5937– 5944. doi:10.4238/2013.november.26.3

 26. Zubiaur P, Soria-Chacartegui P, Koller D, Navares-Gómez M, Ochoa D, Almenara S, et al. Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed Pharmacother. 2021;133: 111087. doi:10.1016/j.biopha.2020.111087

 27. Bet PM, Verbeek EC, Milaneschi Y, Straver DBM, Uithuisje T, Bevova MR, et al. A common polymorphism in the ABCB1 gene is associated with side effects of PGP- dependent antidepressants in a large naturalistic Dutch cohort. Pharmacogenomics J. 2016;16: 202–208. doi:10.1038/tpj.2015.38

 28. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and

 therapeutic response. Ther Drug Monit. 2008;30: 474–482. doi:10.1097/ftd.0b013e31817d6f5d

29. Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.

ABCB1 genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. Am

J Psychiatry. 2015;172: 751–759. doi:10.1176/appi.ajp.2015.14050680

 30. Ho AM-C, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, et al. Mood‐ stabilizing antiepileptic treatment response in bipolar disorder: A genome‐wide association study. Clin Pharmacol Ther. 2020;108: 1233–1242. doi:10.1002/cpt.1982

 31. Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10: 235–242. doi:10.2147/pgpm.s142314

 32. Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13: 150–156. doi:10.9758/cpn.2015.13.2.150

 33. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2 polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647–651. doi:10.1111/j.1755-5949.2012.00336.x

 34. Qian L, Fang S, Yan Y-L, Zeng S-S, Xu Z-J, Gong Z-C. The ABCC2 c.-24C > T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. J Clin Neurosci. 2017;37: 6–14. doi:10.1016/j.jocn.2016.10.014

 35. Xue T, Lu ZN. Association between the polymorphisms in the ATP-binding cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese Han population. Genet Mol Res. 2016;15. doi:10.4238/gmr15048752

 36. Grover S, Kukreti R. A systematic review and meta-analysis of the role ofABCC2variants on drug response in patients with epilepsy. Epilepsia. 2013;54: 936– 945. doi:10.1111/epi.12132

 37. Ma C-L, Wu X-Y, Zheng J, Wu Z-Y, Hong Z, Zhong M-K. Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014;15: 1323–1336. doi:10.2217/pgs.14.89

 38. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11: 25–34. doi:10.1038/tpj.2010.20

 39. Shen C-H, Zhang Y-X, Lu R-Y, Jin B, Wang S, Liu Z-R, et al. Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. Epilepsy Res. 2016;127: 186–190. doi:10.1016/j.eplepsyres.2016.09.004

 40. Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with amotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet. 2015;30: 282–287. doi:10.1016/j.dmpk.2015.05.002